RECOMBINANT DNA GLYCOPROTEIN VACCINE

重组 DNA 糖蛋白疫苗

• 批准号: 3488341
• 负责人: JEFFREY F WILLIAMS
• 金额: $ 5万
• 依托单位: PROBE-TEK, INC.
• 依托单位国家: 美国
• 财政年份: 1985
• 资助国家: 美国
• 起止时间: 1985-04-01 至 1985-09-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3488341
• 关键词: Herpesviridae; Herpesviridae disease; Herpesviridae vaccine; affinity chromatography; antibody neutralization test; antibody specificity; antiviral antibody; enzyme linked immunosorbent assay; gene expression; genetic manipulation; genetic mapping; genetic translation; immunological substance; monoclonal antibody; tissue /cell culture; virus DNA; virus antigen

Feline herpesvirus-1 (FHV-1) is a major pathogen of cats with worldwide distribution. Commercially available live vaccines against FHV-1 are widely used but their recognized serious drawback is the lack of complete attenuation of the virus resulting in the occurrence of vaccine induced clinical signs. The overall objective of the proposed research is to develop a recombinant DNA vaccine against FHV-1 that is safer and more immunogenic then existing products. During phase I a panel of monoclonal antibodies against the surface glycoproteins of FHV-1- will be developed and screened for antigenic specificity and virus neutralizing ability. These monoclonal antibodies are the essential tools for isolation of individual glycoproteins with affinity columns, mapping of the glycoprotein genes and screening of expression vector products, the major objectives of phase II. The value of this system as a model for human herpesvirus vaccine development comes from the fact that it allows definition of glycoprotein induced immunity in the natural host of the disease.

猫疱疹病毒-1（FHV-1）是猫的主要病原体 分配。 针对FHV-1的市售实时疫苗是 广泛使用，但他们公认的严重缺点是缺乏完整的 导致疫苗诱导的病毒的衰减 临床体征。 拟议研究的总体目的是开发重组 针对FHV-1的DNA疫苗比现有的更安全，更免疫原性 产品。 在第一阶段，一组单克隆抗体针对 FHV-1-的表面糖蛋白将开发并筛选 抗原特异性和病毒中和能力。 这些单克隆 抗体是隔离个体的重要工具 具有亲和力柱的糖蛋白，糖蛋白基因的映射和 筛选表达矢量产物，这是II期的主要目标。 该系统作为人疱疹病毒疫苗的模型的价值 发展来自允许定义糖蛋白的事实 诱导的自然宿主的免疫力。